Abstract
This commentary discusses two articles in the current issue of Academic Emergency Medicine that report on investigations of copeptin, a novel biomarker used in conjunction with troponin and an accelerated diagnostic protocol (ADP) in the evaluation of chest pain patients. The authors discuss the challenges and future directions of the evaluation and identification of low-risk chest pain patients who are safe for discharge without additional diagnostic testing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
